Detailed Information

Cited 2 time in webofscience Cited 0 time in scopus
Metadata Downloads

Effect of Human Amniotic Fluid Stem Cells on Kidney Function in a Model of Chronic Kidney Disease

Authors
George, Sunil K.Abolbashari, MehranKim, Tae-HyoungZhang, ChaoAllickson, JulieJackson, John D.Lee, Sang JinKo, In KapAtala, AnthonyYoo, James J.
Issue Date
Nov-2019
Publisher
MARY ANN LIEBERT, INC
Keywords
stem cell therapy; amniotic fluid; chronic kidney disease; kidney regeneration
Citation
TISSUE ENGINEERING PART A, v.25, no.21-22, pp 1493 - 1503
Pages
11
Journal Title
TISSUE ENGINEERING PART A
Volume
25
Number
21-22
Start Page
1493
End Page
1503
URI
https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/38658
DOI
10.1089/ten.tea.2018.0371
ISSN
1937-3341
1937-335X
Abstract
Kidney disease is a major medical problem globally. Chronic kidney disease (CKD) is a progressive loss of kidney function. It causes accumulation of waste and fluid in the body, eventually resulting in kidney failure as well as damaging other organs. Although dialysis and kidney transplantation have been used as primary treatments for renal disease, dialysis does not restore full renal function, and there is a shortage of donor kidneys for transplantation. Recent advances in cell-based therapies have offered a means to augment and restore renal function. Various types of cells have been tested to evaluate their therapeutic effects on injured kidneys. Among various types of cells, amniotic fluid stem cells (AFSCs) share advantages of both embryonic and adult stem cells, such as pluripotent activity, remarkable plasticity, and immunomodulatory effects, which may allow their future therapeutic use as an "off-the-shelf" cell source. AFSC presents advantages of both conventional pluripotent and adult stem cells, such as pluripotent activity, remarkable plasticity, and immunomodulatory effects. This study demonstrates that administration of human-derived AFSC facilitates functional and structural improvement in a rat model of CKD, and suggests that cell therapy with AFSC has potential as a therapeutic strategy to recover renal function in patients with CKD. Impact Statement Patients with chronic kidney disease (CKD) have limited treatment options, and renal transplantation is the only definitive treatment method that restores kidney function. However, challenges associated with transplantation, including donor organ shortage, rejection, and life-long immunosuppression, remain a problem. Recently, stem cell-based therapies have been proposed as an alternative approach to augment and restore renal function. In this study, we used human-derived amniotic fluid stem cells (AFSCs) to treat CKD in a rat model and demonstrated that AFSC treatment facilitated positive effects in terms of improvements of renal function.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > College of Medicine > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Tae-Hyoung photo

Kim, Tae-Hyoung
의과대학 (의학부(임상-서울))
Read more

Altmetrics

Total Views & Downloads

BROWSE